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subcellular fractionationon have been associated with numerous monogenic human diseases typically
classiﬁed as lysosomal storage diseases. However, there is increasing evidence that lysosomal proteins are
also involved in more widespread human diseases including cancer and Alzheimer disease. Thus, there is a
continuing interest in understanding the cellular functions of the lysosome and an emerging approach to this
is the identiﬁcation of its constituent proteins by proteomic analyses. To date, the mammalian lysosome has
been shown to contain ∼60 soluble luminal proteins and ∼25 transmembrane proteins. However, recent
proteomic studies based upon afﬁnity puriﬁcation of soluble components or subcellular fractionation to
obtain both soluble and membrane components suggest that there may be many more of both classes of
protein resident within this organelle than previously appreciated. Discovery of such proteins has important
implications for understanding the function and the dynamics of the lysosome but can also lead the way
towards the discovery of the genetic basis for human diseases of hitherto unknown etiology. Here, we
describe current approaches to lysosomal proteomics and data interpretation and review the new lysosomal
proteins that have recently emerged from such studies.
© 2008 Elsevier B.V. All rights reserved.1. Introduction to the lysosomeDiscovered by Christian de Duve over 50 years ago [1], the
lysosome is a cytoplasmic cellular organelle that has risen to
prominence because of its critical role in cellular function and tissue
homeostasis as well as its involvement in numerous human diseases
(reviewed in [2,3]). Present in all nucleated eukaryotic cells, the
lysosome is delimited by a single-layer lipid membrane and has an
acidic internal pH (∼5) that is maintained by an ATP-dependent
proton pump. The primary cellular function of the lysosome is the
degradation and recycling of macromolecules obtained by endocy-
tosis, autophagy and other cellular trafﬁcking pathways. Several
classes of macromolecules are hydrolyzed including proteins, poly-
saccharides, lipids and nucleic acids and this is achieved by the
concerted action of numerous soluble catabolic enzymes within the
lumen of the lysosome, collectively termed acid hydrolases. Acid
hydrolases have evolved to function in the low pH of this organelle
and possess a wide variety of enzymatic properties. Over 60 of these
enzymes and soluble accessory proteins have been described to date.
A number of studies have investigated the proteome of soluble
lysosomal proteins from a variety of mammalian tissues and cell types
([4]; reviewed in [5]) revealing that, for the most part, these proteins
tend to be fairly ubiquitous. However, some lysosomal proteins havell rights reserved.very limited tissue distribution and perform specialized cellular
functions e.g. the granzymes of immune cells [6].
In addition to the soluble luminal proteins, many integral and
peripheral membrane proteins are associated with the lysosome and
have a variety of functions including catalysis, transmembrane
transport of substrates and digestion products, establishment of pH
gradients, vesicular transport and maintenance of lysosomal struc-
tural integrity [3].
Classical biochemical and genetic analyses have resulted in the
characterization of numerous components of the lysosome. More
recently, the application of highly-sensitive proteomic approaches has
lead to the identiﬁcation of many new proteins that may function in
this compartment and for some, lysosomal localization has now been
veriﬁed. It is these new lysosomal proteins that form the focus of this
review. Approaches to the discovery and validation of lysosomal
candidates have recently been reviewed in depth [5] and for the most
part, will be outlined in brief here.
2. Lysosomes and human disease
The lysosomal system is of considerable biomedical importance as
alterations in lysosomes and lysosomal proteins are associated with
numerous human diseases (Table 1) [3,7]. To date, over 50 monogenic
human genetic diseases have been identiﬁed that are primarily
associated with lysosomal dysfunction and the majority of these are
classiﬁed as lysosomal storage diseases (LSDs). Here, deﬁciencies in
lysosomal proteins, most commonly soluble luminal ones, result in an
Table 1
Established lysosomal proteins and associated human disorders
Protein Disease Protein type Protein function Man6-P
ABCA2 Membrane Lipid metabolism?
ABCB9/TAP-like transporter Membrane Antigen processing
ATPase, V-H+ including ∼13 subunits Kufor–Rakeb syndrome/Parkinson disease 9 Membrane Membrane transporter
CD68 Membrane
CLC-7 Osteopetrosis Membrane Transporter
CLN3 protein Ceroid lipofuscinosis, neuronal 3, juvenile Membrane Unknown
Cystinosin Cystinosis Membrane Transporter
LALP70 Membrane
LAPTM4 Membrane
LIMP-1/CD63/LAMP-3 Membrane
LIMP-2/LGP85 Membrane Lysosomal transport
Lipopolysaccharide-induced TNF factor
LITAF
Membrane
LYAAT-1 Membrane Transporter
Lysosome-associated membrane
protein 1 (LAMP1)
Membrane
Lysosome-associated membrane
protein 2 (LAMP2)
Danon disease Membrane Structural, protein import
Major facilitator superfamily domain
containing 8
Ceroid lipofuscinosis, neuronal 7, late infantile,
variant
Membrane Transporter (?)
Mucolipin Mucolipidosis IV (sialolipidosis) Membrane Membrane transporter
Nicastrin Membrane
NPC1 protein Niemann-pick disease, type C1 Membrane Membrane transporter (?)
Solute carrier family 17 Sialuria (Salla disease) Membrane Membrane transporter
1-O-acylceramide synthase Soluble Catabolic enzyme +
Acid ceramidase Farber disease Soluble Catabolic enzyme +
Acid lipase Wolman disease Soluble Catabolic enzyme +
Alpha-galactosidase A Fabry disease Soluble Catabolic enzyme +
Alpha-L-iduronidase Mucopolysaccharidosis type I (Hurler and Scheie
syndromes)
Soluble Catabolic enzyme +
Alpha-N-acetylgalactosaminidase Schindler disease, type I Soluble Catabolic enzyme +
Alpha-N-acetylglucosaminidase Mucopolysaccharidosis type IIIb (Sanﬁlippo
syndrome B)
Soluble Catabolic enzyme +
Arylsulfatase A Metachromatic leukodystrophy Soluble Catabolic enzyme +
Arylsulfatase B Mucopolysaccharidosis type VI
(Maroteaux-Lamy syndrome)
Soluble Catabolic enzyme +
Beta-galactosidase Mucopolysaccharidosis type IVb (Morquio
syndrome B)
Soluble Catabolic enzyme +
Beta-glucuronidase Mucopolysaccharidosis type VII (Sly syndrome) Soluble Catabolic enzyme +
Beta-hexosaminidase alpha chain Tay–Sachs disease Soluble Catabolic enzyme +
Beta-hexosaminidase beta chain Sandhoff disease Soluble Catabolic enzyme +
Beta-mannosidase Mannosidosis, beta A, lysosomal Soluble Catabolic enzyme +
Carboxypeptidase, vitellogenic-like Soluble Catabolic enzyme ? +
Cathepsin B Soluble Catabolic enzyme +
Cathepsin D Ceroid lipofuscinosis, neuronal 10, congenital Soluble Catabolic enzyme +
Cathepsin F Soluble Catabolic enzyme +
Cathepsin H Soluble Catabolic enzyme +
Cathepsin K Pycnodysostosis Soluble Catabolic enzyme +
Cathepsin L Soluble Catabolic enzyme +
Cathepsin O Soluble Catabolic enzyme +
Cathepsin S Soluble Catabolic enzyme +
Cathepsin Z Soluble Catabolic enzyme +
CLN5 protein Ceroid lipofuscinosis, neuronal 5, late infantile,
variant
Soluble Unknown +
Deoxyribonuclease II Soluble Catabolic enzyme +
Dipeptidyl-peptidase I Papillon-Lefevre syndrome Soluble Catabolic enzyme +
Galactocerebrosidase Krabbe disease Soluble Catabolic enzyme +
Gamma-glutamyl hydrolase Soluble Catabolic enzyme +
Glycosylasparaginase Aspartylglucosaminuria Soluble Catabolic enzyme +
GM2 activator Tay–Sachs disease, AB variant Soluble Accessory protein +
Hyaluronidase Mucopolysaccharidosis type IX (hyaluronidase
deﬁciency)
Soluble Catabolic enzyme +
Iduronate 2-sulfatase Mucopolysaccharidosis type II (Hunter
syndrome)
Soluble Catabolic enzyme +
Interferon gamma inducible protein 30 Soluble Catabolic enzyme +
Legumain Soluble Catabolic enzyme +
Lysosomal alpha-glucosidase Glycogen storage disease II (Pompe disease) Soluble Catabolic enzyme +
Lysosomal alpha-mannosidase Mannosidosis, alpha b, lysosomal Soluble Catabolic enzyme +
Lysosomal protective protein/Cathepsin A Neuraminidase deﬁciency with beta-
galactosidase deﬁciency
Soluble Catabolic enzyme/accessory protein +
Myeloperoxidase Myeloperoxidase deﬁciency Soluble Host defence +
N-acetylgalactosamine-6-sulfatase Mucopolysaccharidosis type IVa (Morquio
syndrome a)
Soluble Catabolic enzyme +
N-acetylglucosamine-6-sulfatase Mucopolysaccharidosis type IIId (Sanﬁlippo
syndrome d)
Soluble Catabolic enzyme +
NPC2 protein Niemann-pick disease, type C2 Soluble Soluble transporter +
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Table 1 (continued)
Protein Disease Protein type Protein function Man6-P
N-sulphoglucosamine sulphohydrolase/
heparan N-sulfatase
Mucopolysaccharidosis type IIIa (Sanﬁlippo
syndrome a)
Soluble Catabolic enzyme +
Palmitoyl-protein thioesterase 1 Ceroid lipofuscinosis, neuronal 1, infantile Soluble Catabolic enzyme +
Palmitoyl-protein thioesterase 2 Soluble Catabolic enzyme +
Saposin Combined saposin deﬁciency; Krabbe disease,
atypical, due to saposin a deﬁciency;
metachromatic leukodystrophy due to saposin B
deﬁciency; Gaucher disease, atypical, due to
saposin C deﬁciency
Soluble Accessory protein +
Sialic acid 9-O-acetylesterase Soluble +
Sialidase 1 Mucolipidosis I (sialidosis) Soluble Catabolic enzyme +
Sialidase 4 Soluble Catabolic enzyme +
Sphingomyelin phosphodiesterase Niemann-Pick disease, type a and b Soluble Catabolic enzyme +
Tartrate-resistant acid phospahatase Soluble Catabolic enzyme +
Tissue alpha-L-fucosidase Fucosidosis Soluble Catabolic enzyme +
Tripeptidyl-peptidase I Ceroid lipofuscinosis, neuronal 2, late infantile Soluble Catabolic enzyme +
Lysosomal acid phosphatase Soluble, membrane associated Catabolic enzyme –
Glucocerebrosidase Gaucher disease Soluble, membrane associated Catabolic enzyme –
Many membrane proteins involved in cellular trafﬁcking have multiple cellular locations and some may be transiently associated with the lysosome (e.g., recycling receptors and
adaptors involved in vesicular targeting).We have therefore limited this list tomembrane proteins that appear to be primarily located to the lysosome andwhich functionwithin this
organelle.
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material primarily represents undigested substrates and may result
in alterations in the ultrastructure of the lysosome that are often
speciﬁc to a given LSD and which may be diagnostically valuable.
Defects in various classes of lysosomal proteins result in disease
(reviewed in [7]) but most LSDs result from mutations in genes
encoding lysosomal enzymes. Other LSDs result from defects in
soluble accessory proteins that are involved in functions such as
presenting substrates to hydrolytic enzymes, membrane proteins that
transport degradation products out of the lysosome or components of
the cellular machinery involved in the processing or trafﬁcking of
lysosomal proteins. Individually, LSDs are rare but as a group, their
frequency is signiﬁcant, with an incidence of ∼1:5000 live births [8].
In addition to these diseases, there is increasing evidence that
lysosomes and lysosomal activities may be involved in more wide-
spread, polygenic diseases such as cancer [9], arthritis [10], athero-
sclerosis [11] and Alzheimer's disease [12]. Of particular recent
interest is the function of the lysosome in cellular autophagic
pathways that may play a protective role against infection, aging,
neurodegeneration and cancer (reviewed in [13]).
3. Signiﬁcance of lysosomal proteomic studies
As interest in the role of the lysosomal system under normal
conditions and in human disease continues to increase, more studies
are being directed towards the elucidation of the mammalian
lysosomal proteome and that of related organelles (reviewed in
[3,5]). Understanding the full range of biological functions of this
organelle provides essential information regarding the normal
function of the cell but may also shed insights into how lysosomes
may inﬂuence general cellular activities in pathogenic states. In some
cases, changes in lysosomal activities may be directly involved in
disease and thus identifying such changes could potentially lead to
novel therapeutic targets. Other alterations in lysosomal activities
may not be directly involved in pathogenesis per se but may reﬂect
disease and could potentially be useful as prognostic or diagnostic
markers. It is worth noting that while select lysosomal activities can
be individually measured in disease samples, the application of
quantitative proteomic approaches can provide a global picture of the
lysosomal system in particular by revealing coordinate alterations in
expression.
Another rationale for the comprehensive characterization of the
mammalian lysosome is that there remain human diseases ofunknown genetic etiology that appear to be lysosomal in origin
based upon morphological or other clinical criteria. For example, the
presence of membrane-delimited storage bodies, especially when
associated with progressive neurodegeneration, would be highly
suggestive of a lysosomal storage disease. There are a number of
clinically deﬁned diseases that fall into this category, notable
examples of which are the adult form of neuronal ceroid lipofuscinosis
and geleophysic dysplasia (reviewed in [5]).
To date, proteomic approaches have led to the identiﬁcation of
three human lysosomal disease genes. In a comparative proteomic
study [14], lysosomal proteins in late infantile neuronal ceroid
lipofuscinosis, a fatal neurodegenerative disease of children, were
compared to those in normal controls. A previously uncharacterized
lysosomal protein was found to be absent in the patient samples and
mutations were subsequently found in its respective gene, con-
ﬁrming it to be the basis for disease. This protein was eventually
demonstrated to be tripeptidyl peptidase I, a lysosomal protease
[15,16].
Two other proteomic studies led to the discovery of disease genes
not by a comparative approach but by instead providing candidates
for further genetic analysis. In a study of puriﬁed soluble lysosomal
proteins, a previously characterized cholesterol binding protein was
found and conﬁrmed to reside within the lysosome [17] and this
information provided a rationale for a genetic screen of this protein in
unsolved lysosomal storage diseases exhibiting cholesterol storage.
Mutations were found in the gene encoding this protein in Niemann-
Pick C Type 2, a neurovisceral disease of children that was of un-
known basis at the time. Mucopolysaccharidosis IIIC (MPSIIIC) is a
lysosomal disease that was known to be caused by a loss of heparan
acetyl-CoA:alpha-glucosaminide N-acetyltransferase (HGSNAT)
activity and while the gene encoding this protein had been mapped
by linkage analysis, it had not been identiﬁed [18]. In a proteomic
study of puriﬁed lysosomal membrane proteins [19], a novel
membrane protein was identiﬁed whose gene mapped to the same
locus as that determined for the defect in MPSIIIC. Subsequent
analysis of this novel lysosomal protein revealed mutations in MPSIIIC
and conﬁrmed that it encoded HGSNAT [20].
In addition to clinically-deﬁned diseases of unknown basis, there
are numerous patients diagnosed with apparent lysosomal storage
disease in which the gene defect cannot be found. Many of these
cases may represent atypical clinical presentation of established
LSDs, often with a mild or delayed onset resulting from partial loss of
function mutations [21]. However, some cases are likely to result
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with human disease while others might be caused by mutations in
genes encoding lysosomal proteins that have not yet been identiﬁed
or assigned to this organelle. In all of these cases, lysosomal pro-
teomic analyses could play a pivotal role in the identiﬁcation of gene
defects.
4. Organellar proteomics, subcellular fractionation and
application to the lysosome
Proteomic characterization of individual organelles [22] can
provide valuable information regarding their function in normal and
disease states. In addition, this type of approach circumvents
analytical issues associated with the complexity of the entire
proteome and represents a tractable method for determining the
proteome of a given tissue or cell type. The most widely applied
approach towards organellar proteomics involves subcellular fractio-
nation, typically by differential and gradient centrifugation, and
protein identiﬁcation using liquid chromatography tandem mass
spectrometry (LC-MS/MS) and these methods can be applied towards
the lysosomal proteome. However, because of the overlapping
physical properties of organelles, the resolution of subcellular
fractionation by density centrifugation is limited, typically allowing
for the enrichment of organelles but not puriﬁcation to homogeneity.
As a result, these experiments are highly susceptible to false positive
errors in assignment of location and datamust be interpreted carefully
with appropriate validation. This problem is compounded by the fact
that some proteins may be present in multiple cellular locations. For
example, proteins derived from mitochondria may be found in both
mitochondria and lysosomes involved in autophagic degradation of
mitochondria. Lysosomal proteins may be found in lysosomes as well
as their sites of synthesis (ER and Golgi) and in transport vesicles.
There are emerging methodological improvements that increase
the accuracy of analytical or preparative subcellular fractionation
approaches to organellar proteomics. In a density gradient, organelles
migrate with overlapping but distinct proﬁles thus, rather than simply
characterizing the proteome of organelle-enriched preparations, one
approach is to use quantitative mass spectrometric methods to
measure the distribution of proteins across the gradient and assign
location by reference to the distribution of marker proteins. Protein
distribution can be measured using quantitative isotopic labeling [23]
or label-free methods [24].
Another approach for deﬁnitive localization is to use methods that
speciﬁcally alter the biophysical properties of organelles, resulting in a
characteristic shift of their density as measured by gradient centrifu-
gation. The distribution of marker enzymes for a given organelle is
thus altered and other proteins with a similar shift in distribution can
thereby be assigned to this compartment. For the lysosome, a selective
shift in buoyant density can be achieved in a number of ways.
Treatment of animals with Triton WR-1339 (tyloxapol) prior to tissue
harvest and subcellular fractionation causes a lysosomal accumulation
of lipids in the so-called “tritosomes” [25,26]. Loss of NPC2, a
lysosomal cholesterol binding protein, results in an accumulation of
cholesterol and other lipids within the lysosome with a concomitant
decrease in density [27]. In addition, treatment of cultured cells with
progesterone also results in a shift in the buoyant density of lysosomes
[28], presumably by blocking cholesterol egress [29]. For each of these
methods, the density of other organelles remains largely unchanged,
thus the shift in distribution represents a speciﬁc test for lysosomal
localization. In the past, such approaches have been limited to the
analysis of proteins for which biochemical tests or immunological
reagents are available. However, the use of mass spectrometry for
protein identiﬁcation and quantitation in subcellular fractionationwill
greatly expand the application of these methods.
A number of studies have used subcellular fractionation to
investigate the lysosomal proteome. In an early study, lysosomeswere prepared from human placenta by Percoll gradient centrifuga-
tion and constituent proteins identiﬁed by N-terminal sequencing by
Edman degradation after fractionation by two-dimensional gel
electrophoresis, resulting in the assignment of eight lysosomal
proteins [30]. In another study, rat liver tritosomes prepared by
sucrose density gradient centrifugation were analyzed using mass
spectrometric methods for protein identiﬁcation and 215 proteins
were conﬁdently identiﬁed [19]. Some of these proteins were
previously designated to be lysosomal but the majority were assigned
to other organelles. While some cellular proteins certainly have
multiple cellular locations, this does illustrate the problems of false
positive localization (discussed earlier) that emerge in the analysis of
organelle-enriched fractions. Methods to address this problem are
discussed below (Section 6).
Protocols have also been established to isolate lysosomes by
selectively loading with dextran [31], iron [32] or gold [33]. These
different approaches undoubtedly have individual merits but, to date,
none have been applied to lysosomal proteomics studies.
5. Afﬁnity puriﬁcation of lysosomal proteins
A subgroup of lysosomal proteins representing the majority of
soluble luminal components can be puriﬁed by afﬁnity chromato-
graphy for proteomic characterization. Newly synthesized lysosomal
proteins contain a speciﬁc carbohydrate modiﬁcation, mannose 6-
phosphate (Man6-P) that is recognized and bound by two Man6-P
receptors (MPRs). MPRs direct the targeting of lysosomal proteins
from the trans-Golgi to an acidiﬁed prelysosomal compartment where
theMan6-Pmodiﬁcation is variably removed depending on tissue and
cell type. Puriﬁed MPRs can be used for the visualization of Man6-P
glycoproteins in biological samples [34]. In addition, when immobi-
lized on a solid support, puriﬁed MPRs can be used for the afﬁnity
puriﬁcation of Man6-P containing proteins which are speciﬁcally
eluted from the immobilized MPR by free Man6-P, an approach ﬁrst
described in an analysis of Man6-P glycoproteins puriﬁed from rat
brain [35].
Early proteomic analyses [35,36] of puriﬁed Man6-P glycoproteins
relied upon N-terminal sequencing for protein identiﬁcation but
subsequent studies have employedmore sensitivemass spectrometric
methods and have focussed on a wide variety of sources of these
proteins. Proteins containing Man6-P have now been afﬁnity-puriﬁed
from 17 different rat tissues [4,35], mouse brain [37] and plasma [38],
human brain [37,39], plasma [40] and urine [36,41]. The same
approach has also been used to purify Man6-P glycoproteins from
media conditioned by mouse osteoclasts that naturally secrete
lysosomal proteins [42], human monocytes and breast cancer cell
lines that were chemically induced to secrete lysosomal proteins
[43,44] or mouse embryonic ﬁbroblasts that secrete lysosomal
proteins in the absence of both MPRs [45]. Taken together, proteomic
analysis of puriﬁed Man6-P glycoproteins has resulted in the
identiﬁcation of 60 known lysosomal proteins as well as numerous
candidates that may also have lysosomal function (reviewed in [5]).
Other classes of proteins are also identiﬁed in these studies including
contaminants that are not speciﬁcally eluted from the immobilizedMPR
(i.e., “sticky” or abundant proteins). In addition, some non-lysosomal
proteins, e.g., lectins and protease inhibitors, may bind and copurify
with true Man6-P glycoproteins. One approach that has proven useful
to differentiate between true Man6-P glycoproteins and other pro-
teins has been to directly identify the site of the N-linked oligosaccha-
ride that contains Man6-P using mass spectrometric methods after
deglycosylation of puriﬁed Man6-P containing glycopeptides with
Endoglycosidase H [37]. This method has veriﬁed the presence of
Man6-P in numerous proteins not previously thought to contain this
modiﬁcation. However, based on the identiﬁcation of proteins known to
contain Man6-P, a signiﬁcant drawback of this approach is that not all
deglycosylated peptides that are known to be present are assigned and
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simply reﬂects the speciﬁc properties (e.g. sequence and size) of a given
peptide that may cause it to be selectively lost during sample
preparation or to be missed by the mass spectrometer because it is
poorly ionized or it is outside the mass range constraints of the
instrument. Alternatively, failure to detect a given Man-6-phosphoryla-
tion site may simply reﬂect low peptide abundance.
It is worth noting that while the majority of soluble lysosomal
proteins are targeted to the lysosome via the Man6P-dependent
pathway, other pathways do exist thus there may be multiple ways
in which a given lysosomal protein can reach its ﬁnal destination.
Some soluble lysosomal proteins are targeted solely by Man6P-
independent routes and will not be afﬁnity puriﬁed on immobilized
MPR. An example is β-glucocerebrosidase which is targeted to the
lysosome via interaction with the lysosomal transmembrane protein
LIMP2 [46].
6. Approaches to distinguish candidate novel lysosomal proteins
from contaminants
In the characterization of lysosomal proteomes prepared by both
subcellular fractionation and afﬁnity puriﬁcation, distinguishing
candidates for novel lysosomal proteins from contaminants and
other classes of protein remains problematic. To some extent,
knowledge-based interpretation of data can be helpful; for example,
homologs of known lysosomal proteins are particularly likely to reside
within this organelle. An example is acid-sphingomyelinase like 3A,
which has been found in numerous subcellular fractionation and
afﬁnity puriﬁcation studies and which is almost certainly a true
lysosomal protein. However, this sort of analysis fails with proteins
where a known or predicted function remains to be determined. An
example of such a protein is mammalian ependymin-related protein 1,
which is lysosomal [27,45] but of completely unknown function. Given
that many of the most interesting new lysosomal proteins will be
those of novel function, better methods to differentiate between
candidates and other proteins are needed.
Methods based upon quantitative LC-MS/MS are now beginning to
emerge that can help with this challenging problem. Schröder et al.
[47] have recently reported an analysis of lysosomal membrane
proteins isolated from human placenta and while the preparative
approaches were conventional, this study differs from previous
analysis of similar samples in that a statistical analysis was
incorporated to exclude contaminants [47]. In this approach, a
lysosomal “dense pool” fraction which contained lysosomes, mito-
chondria and other material, was ﬁrst prepared from placenta by
Percoll gradient centrifugation. Lysosomes were disrupted by incuba-
tion with methionine methyl ester, which is hydrolyzed within the
lysosome resulting in their selective disruption via osmotic stress.
Mitochondria were then removed by sucrose density gradient
centrifugation and lipofuscin removed by a further Percoll gradient,
resulting in an apparently homogeneous lysosomal membrane
preparation. The lysosomal membrane and the dense pool samples
were then analyzed by LC-MS/MS and enrichment in the former
determined by spectral counting, a semiquantitative method for
measuring relative protein abundance [48]. Based upon known
lysosomal proteins, a threshold for enrichment was established and
this was used to ﬁlter the data set together with a threshold for the
probability of enrichment. This resulted in exclusion of the majority of
known mitochondrial, ER, plasma membrane and peroxisomal
proteins identiﬁed and allowed for the most accurate description of
the lysosomal membrane proteome to date. However, while this study
certainly represents a signiﬁcant step forward in subcellular fractio-
nation-based lysosomal proteomics, one limitation is that lysosomal
constituents cannot be distinguished from proteins undergoing
degradation within the lysosomal compartment. In order to achieve
this, it will be necessary to follow the total distribution of candidateproteins in all subcellular and extracellular fractions, not just the
lysosome.
For preparations of afﬁnity puriﬁedMan6-P glycoproteins, a recent
approach to exclude contaminants is based upon a comparison
between mock and speciﬁc eluates of the immobilized MPR afﬁnity
columns [4]. After loading and washing, columns are ﬁrst eluted with
buffer containing mannose and glucose 6-phosphate (the “mock”
eluate) then eluted with buffer containing Man6-P (the speciﬁc
eluate). Spectral counting was then used to estimate the relative
abundance of each identiﬁed protein in both eluates with the
prediction that true Man6-P glycoproteins (but possibly also proteins
that do not contain Man6-P but which associate with Man6-P
glycoproteins, depending upon the strength of interaction) should
be enriched in the Man6-P eluate relative to the mannose/glucose 6-
phosphate eluate. In contrast, non-speciﬁc contaminants (i.e., abun-
dant or “sticky” proteins that leach from the column in a Man6-P
independent manner) should be present at equal or greater levels in
the mock compared to speciﬁc eluate. Based upon known lysosomal
proteins, this prediction proved to be the case, with 59/60 of these
proteins with the lower 95% conﬁdence interval of the enrichment
ratio being greater than 2.75 [4]. Spectral count analysis revealed 52
proteins that are not currently assigned to the lysosome that were
similarly enriched and thus represent primary candidates for
lysosomal localization. In concept, the approach of comparing protein
levels inmock versus speciﬁc afﬁnity column eluates is similar to the I-
DIRT procedure for identifying speciﬁc members of a protein complex
that are isolated by the afﬁnity tagging of one of its constituents [49].
However, one important difference is that estimation of protein levels
in the MPR afﬁnity column eluates was achieved by spectral counting
rather than isotopic labelling. This decreases the number of experi-
mental manipulations and simpliﬁes data analysis but there are
limitations to this approach.
Inherent to the use of spectral counting as a tool in assigning
lysosomal localization in experiments based upon subcellular fractio-
nation or afﬁnity chromatography is that the conﬁdence of the
conclusions are highly dependent on the number of spectra observed.
Statistical theory allows calculation of conﬁdence intervals for the
relative abundance ratio of a protein in two samples of interest [4,38].
The 95% conﬁdence intervals are quite wide for proteins with low
spectral counts and, as a result, signiﬁcant conclusions are frequently
difﬁcult to make with respect to less abundant proteins in a mixture.
Targetedmass spectrometric analyses that limit sampling of abundant
species and promote sampling of minor species may help. However,
measurement of protein abundance using isotope labeling methods is
much less dependent on the number of spectra assigned to an
individual protein and may be especially useful in investigating low
abundance proteins. These approaches or others quantitative meth-
ods, e.g. peptide peak integration combined with high-resolution MS,
are likely to have increasingly signiﬁcant application in the investiga-
tion of lysosomal proteomes.
7. Approaches to the validation of lysosomal candidates
Novel lysosomal candidates can be identiﬁed by MPR afﬁnity
puriﬁcation or by subcellular fractionation but for either approach,
there remains a need for the validation of cellular location. Most
proteins containing Man6-P reside within the lysosome but there are
some that contain this modiﬁcation that do not reside within this
organelle or which may do so only transiently (e.g., glycoproteins that
are aberrantly phosphorylated and thus targeted to the lysosome
where they are rapidly degraded). Proteins assigned to the lysosomal
compartment by subcellular fractionation could represent new
lysosomal proteins or alternatively, they could be contaminants
from other organelles, proteins undergoing degradation in the
lysosome or proteins that associate with the lysosomal membrane
after cell lysis.
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particular merits and limitations (reviewed in [5]). First, morpholo-
gical approaches to compare the cellular distribution with lysosomal
markers can provide valuable information. Endogenous or recombi-
nant expressed proteins can be detected immunohistochemically or
by tagging with a recombinant epitope or ﬂuorescent protein but
there are drawbacks: generation and validation of antibodies can be
difﬁcult and time-consuming for previously uncharacterized proteins;
immuno- or ﬂuorescent tags are prone to degradation in the protease
rich environment of the lysosome [45,50]; and expression of
lysosomal proteins at supraphysiological levels can result in incorrect
intracellular targeting or secretion from the cell [51,52], complicating
assignment of cellular location. Second, analytical subcellular fractio-
nation can provide a powerful tool in determining the subcellular
localization of a protein of interest, especially when combined with
methods that elicit a speciﬁc shift in lysosome density as discussed
earlier. Again, however, antibody reagents may be required for those
proteins that lack a functional assay.
8. Novel lysosomal M6P-containing proteins
Increasingly sensitive mass spectrometry techniques for protein
identiﬁcation have resulted in the identiﬁcation of a large number of
proteins from numerous sources when puriﬁed by afﬁnity chroma-
tography on immobilized MPRs. These proteins can be classiﬁed into
a broad range of categories based upon their known or predicted
properties: 1) known lysosomal Man6-P glycoproteins; 2) poten-
tially new lysosomal proteins; 3) proteins assigned to cellular com-
partments other than the lysosome and 4); probable contaminants.
Here, we will summarize the current state of knowledge regarding
some potentially new lysosomal proteins and also discuss a number
of proteins that have been demonstrated to contain Man6-P but
which have been assigned to other cellular or extracellular loca-
tions. For consistency, human gene nomenclature is used even
though for some proteins, orthologs in mouse and rat were originally
identiﬁed.
The following proteins have been identiﬁed in proteomic analyses
of puriﬁed Man6-P glycoprotein preparation and may represent new
lysosomal proteins. Table 2 summarizes the reports in which each
protein was identiﬁed and summarizes evidence for lysosomal
localization including whether the presence of Man6-P has been
directly veriﬁed using mass spectrometric methods [37].
8.1. Acid sphingomyelinase-like phosphodiesterase 3a (SMPLD3a)
SMPDL3awas ﬁrst identiﬁed as an interacting partner of the tumor
suppressor gene DBC1 (formerly DBCCR1) in a yeast 2-hybrid screen
[53]. The biological signiﬁcance of this potential interaction is not
known and remains to be corroborated by other approaches. The
cellular function of SMPDL3a is not known. The eponym sphingo-
myelinase-like is inferred from its homology (30% identical, 47%
similar) to lysosomal acid sphingomyelinase but such an activity has
not yet been demonstrated by biochemical means.
8.2. Cellular repressor of E1A-stimulated genes (CREG1)
CREG1was ﬁrst described as a cellular proteinwith some sequence
similarity to the adenoviral E1A oncogene that was proposed to play a
role in transcriptional regulation of cell growth and differentiation
[54]. CREG1 is a 220 amino acid glycoprotein that is secreted when
overexpressed and which has been also suggested to function
intracellularly as a transcriptional repressor by counteracting E1A in
human teratocarcinoma cells [55]. CREG1 has also been suggested to
promote differentiation and cell growth arrest by the inhibition of
ERK1/2 in cultured vascular smoothmuscle cells [56]. Secreted CREG1
binds to the MPR300 (CI-MPR; M6P/IGF2R) in a glycosylation-dependent manner and has been directly demonstrated to contain
Man6-P residues [37,45,55]. Endogenous CREG1 did not co-localize
with LAMP-1 [55] whereas other studies [45] could show that after
internalization in human ﬁbroblasts, a C-terminal tagged version of
CREG1 localizes to LAMP1-positive lysosomes. In addition, in
subcellular fractionation analyses of rat liver, CREG1 was found to
codistribute with lysosomal markers in untreated rats and rats treated
with Triton WR-1339 (M. Qian and Lobel, unpublished data) (see
Section 4). Recently, a lysosomal localization for CREG1 was unequi-
vocally demonstrated by subcellular fractionation and immunoloca-
lization [57] although its function within this organelle remains to be
elucidated.
8.3. Arylsulfatase G (ARSG)
Initially identiﬁed by a bioinformatic search of EST databases
[58], ARSG is a novel sulfatase gene with signiﬁcant similarity to
lysosomal arylsulfatase A (37% identical, 50% similar). Initial studies
of recombinant ARSG expressed in COS-7 cells suggested that it was
localized to the ER [58] but the isolation of this protein by MPR-
afﬁnity puriﬁcation and veriﬁcation of Man6-phosphorylation
strongly suggested lysosomal localization. A subsequent study also
showed that this protein binds MPR and importantly, conﬁrmed a
lysosomal localization by immunohistochemistry [59]. In the same
study, ARSG was also demonstrated to have sulfatase activity at
acidic pH.
8.4. Arylsulfatase K, telethon sulfatase (ARSK)
Another member of the arylsulfatase family, ARSK, was also
identiﬁed by bioinformatic analyses [60] and later identiﬁed by
MPR-afﬁnity puriﬁcation and shown to contain Man6-P. ARSK is a 536
amino acid protein with relatively little homology with other
sulfatases (up to 22% identity) and such an activity has yet to be
demonstrated experimentally. The precise spatial orientation of key
amino acids are essential for sulfatase function and these are
conserved in ARSK, consistent with a sulfatase activity [61].
8.5. N-acylsphingosine amidohydrolase (acid ceramidase)-like (NAAA)
Isolated by MPR-afﬁnity puriﬁcation from mouse brain, NAAA is
a 359 amino acid N-acylethanolamine-hydrolyzing acid amidase
that is related (33% identical, 52% similar) to the established
lysosomal acid ceramidase. NAAA was ﬁrst puriﬁed from human
megakaryoblastic cells [62] and subsequently found in various rat
tissues [63]. GFP-tagged NAAA derivatives were originally suggested
to localize within the lysosome [64,65] and recently, this has been
demonstrated for the endogenous protein [66]. NAAA was originally
found to hydrolyze anadamide at acidic pH [62] and later shown to
hydrolyze bioactive N-acylethanolamines into free fatty acids and
ethanolamine [65].
8.6. Mannose-6-phosphate protein P76 (P76, LOC196463)
P76 (formerly hypothetical protein LOC196463) was ﬁrst identiﬁed
as a relatively abundant constituent of preparations of Man6-P
glycoproteins from humans and rodents and has now been convin-
cingly demonstrated to be located within the lysosome [45,67,68].
Recombinant P76 was internalized and delivered to the lysosome of
cultured cells in a MPR-dependent manner [45] and, consistent with
this observation, carbohydrate residues containing Man6-P were
identiﬁed at 5 of 6 potential N-linked glycosylation sites of P76
isolated from human brain [37]. It is synthesized as single chain
precursor that is processed to multiple smaller chains [37,45,67,68]
The function of P76 is not known. This protein has signiﬁcant
homology (36% identical, 52% similar) with phospholipase B
Table 2
Potentially novel soluble lysosomal proteins that were identiﬁed in Man6-P glycoproteomic analyses
Protein Gene Ref. M6P sites veriﬁed Lysosomal validation
Acyloxyacyl hydrolase AOAH b, c Yes
Arylsulfatase G ARSG h Yes
Arylsulfatase K ARSK c, h, i Yes
N-acylsphingosine amidohydrolase 2 ASAH2 h
N-acylethanolamine-hydrolyzing acid amidase NAAA h, i
Biotinidase precursor BTD c, f, h, i Yes
Cat eye syndrome critical region 1 CECR1 c, f, g Yes
Clusterin CLU c, f, h, i
Cellular repressor of E1A-stimulated genes CREG1 a, b, c, d, f, i Yes Morphological, subcellular fractionation⁎
Deoxyribonuclease 1 DNASE1 g, i
Mammalian ependymin related protein 1 EPDR1 c, d, f, h, i Yes Morphological, subcellular fractionation
Epididymis-speciﬁc alpha-D-mannosidase MAN2B2 a, c, d, e, f, g, h, i Yes
ER aminopeptidase 1 ERAP1 f, i
Hypothetical protein FLJ22662 FLJ22662 c, f, g, i Yes
Plasma alpha-L-2-fucosidase FUCA2 c, f, i Yes
Interleukin-4-induced gene 1 IL4I1 e, i Morphological
Mannose-6-phosphate protein P76 LOC196463 c, d, f, g, h, i Yes Morphological, subcellular fractionation
Phospholipase D3 PLD3 c, h, i
Procollagen-lysine 1,2-oxoglutarate 5-dioxygenase 1 PLOD1 b, e, f, g, i
Protein O-fucosyltransferase 1 POFUT1 h, i
Protein O-fucosyltransferase 2 POFUT2 c, f, h, i Yes
Prostaglandin-H2 D-isomerase PTGDS c, f, h Yes
Pancreatic ribonuclease RNASE1 g, f
Ribonuclease 6 RNASE6 d, f, g, i
Ribonuclease T2 RNASET2 c, e, f, g, h, i Subcellular fractionation
Serine carboxypeptidase 1 SCPEP1 c, d, e, h, i Yes Morphological, subcellular fractionation⁎
Neuroserpin SERPINI1 c, i Yes
Acid sphingomyelinase-like phosphodiesterase 3A SMPDL3A c, e, f, g, h, i Yes
Microsomal stress 70 protein ATPase STCH c, f, g, i Yes
Sulfatase modifying factor 2 SUMF2 c, f, i Yes
References are: a, Journet et al. [43], Electrophoresis 21, 3411–3419; b, Journet et al. [44], Proteomics 2, 1026–1040; c, Sleat et al. [39], Proteomics 5, 1520–1532; d, Kollmann et al. [45],
Proteomics 5 3966–3978; e, Czupalla et al. [42], Mol Cell Proteomics 5, 134–143; f, Sleat et al. [37], Mol Cell Proteomics 5, 1942–1956.; g, Sleat et al. [5], Biochim Biophys Acta 1774,
368–372 ; h, Qian et al. [35], Mol Cell Proteomics 7, 58–70; and i, Sleat et al. [4], J Prot Research 7, 3010–3021.
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tion in lipid metabolism has been suggested but this remains to be
demonstrated. Interestingly, an apparent lysosomal acid phospholi-
pase B activity was demonstrated using an electron microscopic
approach in liver and kidney from mice [69].
The highly glycosylated P67 from Trypanosoma brucei displays
28% identity to human P76 but differs in an additional C-terminal
transmembrane domain and thus resembles the lysosomal integral
membrane proteins LAMP-1/-2 from a structural point of view [70].
The depletion of P67 in trypanosomes by RNAi knockdown drama-
tically alters lysosomal morphology and function and eventually
leads to retarded growth and death of the parasite in the mam-
malian bloodstream [71]. In RNAi-treated trypanosomes of blood-
stream origin, lysosomes were extremely enlarged (4–6 times) and
exhibited autophagosome-like membranes [71]. The observation
that ablation of the trypanosome ortholog of P76 results in a severe
lysosomal defect suggests that this protein may well be worth
further investigation in human lysosomal storage diseases of un-
known etiology.
8.7. FLJ22662
A second member of the phospholipase B-related family, FLJ22662
is located on chromosome 12p13 and encodes a protein that is
predicted to be 552 amino acids long and which is 32% identical to
P76. Like P76, a potential catalytic function for this protein remains to
be determined.
8.8. Mammalian ependymin-related protein 1 (EPDR1)
First puriﬁed from rat brain [35], human and rodent EPDR1 have
since been found in most proteomic analyses of M6P-glycoproteins.EPDR1 contains at least one carbohydrate with Man6-P and has been
clearly demonstrated to reside within the lysosome [27,45]. EPDR1 is
named after ependymin which is a predominant glycoprotein in the
cerebrospinal ﬂuid of teleost ﬁshes [72]. Piscine ependymins have
been suggested to be associated with neoplasticity and regeneration
of the brain by modulating calcium homeostasis (reviewed in [73]).
Mammalian EPDR1 was ﬁrst described as a gene that was shown to be
upregulated in human colorectal tumor specimens (hence designated
“upregulated in colorectal cancer gene-1”) [74] and down-regulated
in hematopoetic cells [75]. While EPDR1 is clearly lysosomal,
homology searching fails to any signiﬁcant similarity to other proteins
of known function that might provide clues to its cellular role. From
this perspective, EPDR1 represents a particularly interesting new
lysosomal protein that will require further investigation to ascertain
its function.
8.9. Serine carboxypeptidase 1, retinoid-inducible serine
carboxypeptidase (SCPEP1)
SCPEP1 was originally identiﬁed in a screen for genes responding
to retinoic acid in rat vascular smooth muscle cells [76]. SCPEP1 is
classiﬁed as a member of the serine carboxypeptidase family S10
which is characterized by a catalytic triad of Ser, Asp and His and
which exhibit peptidase activity at acidic pH, which is consistent
with lysosomal function [77]. SCPEP1 is 23% identical to the lyso-
somal serine carboxypeptidase protective protein/cathepsin A and
20% identical to vacuolar carboxypeptidase Y from S. cerevisiae. The
35 kDa mature SCPEP1 arises from a 51 kDa precursor and both a C-
terminally ﬂuorescent-tagged derivative and the endogenous pro-
tein have been shown to localize to the lysosome [45,78]. However,
to date, no enzymatic activity has been demonstrated for SCPEP1
[78].
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In addition to thewell known lysosomal acid alpha-D-mannosidase
(MAN2B1), MAN2B2 was puriﬁed as a second alpha-D-mannosidase
in porcine epididymal ﬂuid [79]. The 135 kDa MAN2B2 precursor is
processed into subunits with apparent molecular weights of 63 kDa
and 51 kDa, respectively [79]. The mouse ortholog is ubiquitously
expressed [80]. Identiﬁed in most studies of puriﬁed Man6-P glyco-
proteins, human MAN2B2 has recently been shown to preferentially
cleave the core alpha 1,6-mannose residue from the Man3-GlcNAc but
not fromMan3-GlcNAc2 or larger highmannose oligosaccharides [81].
A lysosomal alpha-mannosidase speciﬁc for alpha 1,6-linked core
mannose residues, probably representing MAN2B2, was partially
puriﬁed from human alpha-mannosidosis ﬁbroblasts, human spleen
and rat liver [82–84].
8.11. Ribonucleases 1, 6 and T2 (RNASE1, RNASE6, RNASET2)
Three ribonucleases have been puriﬁed by MPR afﬁnity chromato-
graphy including pancreatic ribonuclease (RNASE1), ribonuclease 6
(RNASE6) and ribonuclease T2 (RNASET2) and these are promising
lysosomal candidates due to their respective hydrolytic activities. For
RNASET2, Man6-phosphorylation has been experimentally veriﬁed
[37] and a lysosomal localization was recently demonstrated by
subcellular fractionation [85].
8.12. Cat eye syndrome critical region 1 (CECR1)
CECR1 is a human homolog of insect-derived growth factor and
encodes an adenosine deaminase isoenzyme (ADA2) that was found
at low levels in human serum and may be active at sites of
inﬂammation during hypoxia and of tumor growth [86]. Interestingly,
the pH optimum for adenosine deaminase activity is slightly acidic
(∼pH 6.6) which could reﬂect a lysosomal function.
8.13. Acyloxyacyl hydrolase (AOAH)
AOAH speciﬁcally deacylates bacterial lipopolysaccharide endo-
toxins and in doing so, is thought to play an important role in host
defence. This protein has some sequence similarity with lysosomal
saposins, has been experimentally determined to contain Man6-P, can
be endocytosed in an MPR-dependent manner [87], has a pH optima
for catalytic activity between 5 and 6 depending on substrate [88] and,
when expressed in BHK cells, it is present in vesicular cytoplasmic
bodies [89]. All of these observations are consistent with a lysosomal
localization.
A number of proteins that are routinely identiﬁed in MPR-afﬁnity
puriﬁed preparations are not currently assigned to the lysosome but
are assigned to cellular compartments or thought to be secreted. SomeTable 3
Novel lysosomal membrane proteins
Membrane proteins Gene Ref.
Lysosomal p40 C2orf18 a, e
Transmembrane protein 74 TMEM74 f
Heparan-α-glucosaminide N-acetyl-transferase (TMEM76) HGSNAT b, c, e
Major facilitator superfamily domain containing 8 protein
(MFSD8 alias CLN7)
MFSD8 d, e
LOC201931 alias FLJ38482 TMEM192 e
C7orf28A alias LOC51622 C7orf28A e
References are: a, Boonen et al. [90], Biochem J 395, 39–47; b, Fan et al. [20], Am J Hum Gene
Am J Hum Genet 81, 136–146; e, Schröder et al. [47], Trafﬁc 8, 1676–1686; and f, Yu et al. [9
Φ, large hydrophobic amino acid.of these proteins may be incorrectly assigned or they may have
multiple cellular locations. A number of ER/Golgi proteins are
frequently seen, including procollagen-lysine 1,2-oxoglutarate 5-
dioxygenase 1 and microsomal stress 70 protein ATPase [5]. In
addition, numerous abundant plasma proteins have also been found
and surprisingly shown to contain Man6-P [40]. The signiﬁcance of
Man6-P on these proteins is unclear but it is possible that they may
simply represent low afﬁnity substrates for the lysosomal phospho-
transferase that receive the Man6-P modiﬁcation to some degree. For
ER/Golgi proteins, this may simply reﬂect spatial proximity to the
phosphotransferase. For abundant plasma proteins, this may reﬂect
their high abundance within the biosynthetic secretory pathway
combined with the fact that they are low afﬁnity ligands for the
lysosomal enzyme phosphotransferase, resulting in a proportion of
each receiving the Man6-P modiﬁcation. Thus, while a lysosomal
function for some of these glycoproteins cannot be ruled out, further
studies are needed to understand the signiﬁcance of Man6-phosphor-
ylation in these cases.
9. Novel lysosomal membrane proteins
Subcellular fractionation, genetic and other approaches have
recently led to the discovery of several new lysosomal membrane
proteins and provided many candidates for localization to this
compartment (summarized in Table 3).
9.1. Lysosomal p40 (C2orf18)
Lysosomal p40 (gene name 4930471M23Rik) was originally
identiﬁed in a preparation of lysosomal membranes derived from rat
liver lysosomes [90]. Lysosomal localizationwas subsequently demon-
strated by cosedimentation with lysosomal marker proteins after
subcellular fraction and colocalization of GFP-tagged versions of p40
with LAMP-1 [90]. Mouse p40 is a highly hydrophobic integral
membrane protein that has between seven to ten transmembrane
domains that are linked to each other by relatively short loops. Unlike
most lysosomal membrane proteins, p40 does not contain any N-
linked carbohydrate residues. The lysosomal half-life of p40 was
estimated to be ∼10 h [90] which is comparable with highly-
glycosylated proteins such as LAMP-1 or LIMP-1, -2 or -3 for which
deglycosylation results in an increased proteolysis [91,92]. Sequence
homologies suggest that p40 may function as a lysosomal nucleotide-
sugar transporter.
9.2. Transmembrane protein 74 (TMEM74)
Initially, TMEM74 was identiﬁed in a genetic screen for human
ORFs that could promote autophagy in cultured cells [93]. TMEM74 is
a 305 amino acid protein with a predicted molecular weight ofPutative sorting signals (exxxll-like, yxxΦ-like) Lysosomal validation
Yes Morphological, subcellular
fractionation
Yes, depending on orientation Morphological
Yes Morphological
Yes Morphological
Yes Morphological
Yes, depending on orientation Morphological
t 79, 738–744; c, Hrebicek et al. [96], Am J Hum Genet 79, 807–819; d, Siintola et al. [98],
3], Biochem Biophys Res Commun 369, 622–629.
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lacks homology to other proteins that may provide clues to its
molecular role. However, TMEM74-GFP fusion protein was shown to
localize to lysosomes and autophagosomes and it appears important
in the regulation of autophagy [93] as its ablation by RNAi approaches
strongly inhibited starvation-induced autophagy.
9.3. Heparan-alpha-glucosaminide N-acetyltransferase
(HGSNAT, TMEM76)
Heparan alpha-glucosaminide N-acetyltransferase activity has long
been associated with the lysosomal compartment and with the
lysosomal storage disorder mucopolysaccharidosis IIIC (MPS IIIC, or
Sanﬁlippo C) [94]. Prior to its discovery, a transmembrane acetylation
model was hypothesized in which HGSNAT was proposed to be a
membrane protein that transfers acetyl-residues from cytosolic acetyl-
CoA onto luminal heparan sulfate [95]. Despite these insights into the
mechanism of HGSNAT action, its gene was not identiﬁed until 2006,
when twogroups reported its discoveryusingdifferent approaches. One
study used a traditional genetic linkage analysis of 27 patients and 17
unaffected relatives [96] while the other used a proteomic candidate
approach (see above) [20]. HGSNATconsists of 635 amino acids with 11
predicted transmembrane domains and several tyrosine-based and di-
leucine motifs in its cytosolic C-terminus for lysosomal targeting. The
lysosomal localisation of HGSNAT was conﬁrmed by immunoﬂuores-
cence studies and wild type HGSNAT cDNA was shown to functionally
reconstitute N-acetyltransferase activity in ﬁbroblasts of MPS IIIC
patients. Subsequent studies of MPS IIIC patients have revealed a
range of mutations in HGSNAT [20,96,97].
9.4. Major facilitator superfamily domain containing 8 protein
(MFSD8, CLN7)
Mutations in the MFSD8 gene are the molecular cause of variant
late-infantile-onset neuronal ceroid lipofuscinosis (LINCL) in a
subset of Turkish LINCL patients [98]. MFSD8 encodes a highly
conserved 518 amino acids protein with a calculated molecular
weight of ∼58 kDa and 12 predicted transmembrane domains.
Expression of a tagged version of MFSD8 in COS-1 and HeLa cells
predominantly resulted in lysosomal localization [98]. The mole-
cular function ofMFSD8 is unknown but its afﬁliationwith themajor
facilitator superfamily in combination with homology to different
transporter domains argues for a lysosomal transporter function.
Proteomic analysis has also identiﬁed this protein as a component of
the lysosome [47].
9.5. Other new lysosomal membrane proteins
The innovative recent study of human placental lysosome mem-
branes by Schröder et al. [47] used a statistical analysis of mass
spectrometry data to differentiate lysosomal proteins from contami-
nants (see Section 6) and has yielded numerous candidate lysosomal
proteins for further evaluation. Enriched in the lysosomal fractionwere
28 proteins not previously assigned to this location, of which 12were of
unknown function.As a test of this approach, the subcellular localization
of two of these proteins, TMEM92 and C7orf28A, was examined with
YFP-tagged derivatives. Both localized to the lysosome indicating that
the approach appears to provide reliable data. This study represents the
most rigorous analysis of the lysosomal membrane proteome to date
and provides convincing evidence that there are numerous lysosomal
membrane proteins that remain to be characterized.
10. Concluding remarks
The multiple approaches towards the isolation and identiﬁcation of
lysosomal proteins described here have already generated a lengthy listof potential novel candidates for residence in this organelle. The list of
potentially new lysosomal proteins is likely to continue to growwith the
discovery of other proteins that are restricted to particular cells or tissues
that have yet to be analyzed using proteomic approaches. This is
illustrated with a recent analysis of multiple rat tissues [4] that has
yielded evenmore potential lysosomal candidates. In addition, improve-
ments in the sensitivity and accuracy ofmass spectrometricmethods for
protein identiﬁcationwill increasingly facilitate the identiﬁcation of low
abundance constituents of mixtures of lysosomal proteins.
Despite considerable progress, there remain signiﬁcant obstacles to
a complete characterization of the composition and function of the
lysosome using proteomic approaches. First, as methods for protein
identiﬁcation become more sensitive, contaminants, as well as bona
ﬁde lysosomal proteins, will increasingly be identiﬁed, potentially
resulting in more false positive assignments to the lysosome. To a
degree, the problems associatedwith differentiating between proteins
of interest and contaminants is countered by an increasing general
awareness of the need for parallel control samples inproteomic studies
together with robust biostatistical methods for data analysis [49].
Second, in validating candidates identiﬁed by both subcellular
fractionation and MPR-afﬁnity chromatography, it is likely that in
future it may be insufﬁcient to simply show that a given protein can
localize to the lysosome as this will not differentiate functional
lysosomal components from proteins undergoing lysosomal degrada-
tion or the small proportion of some proteins that may aberrantly
receive the Man6-P modiﬁcation and be targeted to and stable in the
lysosome. It is thus becoming clear that, in the validation of lysosomal
candidates, it is necessary to not only demonstrate a lysosomal
localization but also determine the proportion of the endogenous
protein that resideswithin this compartment. Thirdly,manyof the new
lysosomal proteins that are beginning to emerge are of completely
unknown function, and while knowing that they are lysosomal is
valuable in its own right, a lack of functional information limits our
understanding of the global role of the lysosomal system. In many
cases, as described earlier, homology with proteins of known
function can provide useful clues, but this is not always the case
(e.g. EPDR1). Understanding the role of such proteins is of particular
interest as they could potentially facilitate completely new lysosomal
functions. Future studies using genetic approaches in model
organisms may be helpful in such cases and may also highlight
possible human diseases that might arise from their deﬁciency.
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